Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML2646

Sigma-Aldrich

CX614

≥98% (HPLC)

Sinónimos:

2,3,6a,7,8,9-Hexahydro-11H-1,4-dioxino[2,3-g]pyrrolo[2,1-b][1,3]benzoxazin-11-one, 2H,3H,6aH-Pyrrolidino[2",1"-3′,2′]1,3-oxazino[6′,5′-5,4]benzo[e]1,4-dioxan-10-one, BDP 37, BDP-37, CX 614, CX-614, LiD 37

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C13H13NO4
Número de CAS:
191744-13-5
Peso molecular:
247.25
Número MDL:
MFCD13248581
Código UNSPSC:
12352200
NACRES:
NA.77

Ensayo

≥98% (HPLC)

Formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

cadena SMILES

N21C(Oc3c(cc4c(c3)OCCO4)C2=O)CCC1

InChI

1S/C13H13NO4/c15-13-8-6-10-11(17-5-4-16-10)7-9(8)18-12-2-1-3-14(12)13/h6-7,12H,1-5H2

Clave InChI

RQEPVMAYUINZRE-UHFFFAOYSA-N

Acciones bioquímicas o fisiológicas

Brain-penetrant class I ampakine with AMPA receptor (AMPAR; iGluR) positive allosteric modulator (PAM) activity both in vitro and in vivo.
CX614 (BDP-37) is a brain-penetrant class I ampakine (benzoxazine subgroup of benzamide-type) with AMPA receptor (AMPAR; iGluR) positive allosteric modulator (PAM) activity via targeting a binding site shared by cyclothiazide (CTZ), but distinct from that of GYKI 52466. CX614 enhances field excitatory postsynaptic potentials (amplitude & duration) in rat hippocampal slices and autaptically evoked excitatory postsynaptic currents in neuronal cultures (EC50 of 20-40 μM) by blocking desensitization and slowing deactivation of responses to glutamate. CX614 is also widely employed for studying AMPAR-mediated physiological responses in vivo (1-10 mg/kg n rats and mice via i.p.).

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000138945
0000087539
0000078576

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Daniel P Radin et al.
Biochemical pharmacology, 148, 308-314 (2018-01-14)
It was previously reported that Stargazin (STG) enhances the surface expression of AMPA receptors, controls receptor gating and slows channel desensitization as an auxiliary subunit of the receptors. Ampakines are a class of AMPA receptor positive allosteric modulators that modify
Daniel P Radin et al.
Anticancer research, 38(6), 3461-3465 (2018-06-01)
Mounting evidence suggests that trophic cell signaling can be mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation. It has been demonstrated that exogenous application of brain-derived neurotrophic factor (BDNF) is highly neuroprotective in vitro against neurotoxic insults such as standard chemotherapies.
U S Hess et al.
Neuroscience, 121(2), 509-521 (2003-10-03)
It has been proposed that glutamatergic and dopaminergic systems are functionally opposed in their regulation of striatal output. The present study tested the effects of drugs that enhance AMPA-receptor-mediated glutamatergic transmission (ampakines) for their effects on dopamine-related alterations in cortical
L Cavalleri et al.
Molecular psychiatry, 23(4), 812-823 (2017-11-22)
Among neurobiological mechanisms underlying antidepressant properties of ketamine, structural remodeling of prefrontal and hippocampal neurons has been proposed as critical. The suggested mechanism involves downstream activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, which trigger mammalian target of rapamycin (mTOR)-dependent structural plasticity
Daniel P Radin et al.
Anticancer research, 38(1), 265-269 (2017-12-27)
The 5-year survival rate of glioblastoma (GBM) is ~10%, demonstrating that a new therapeutic modality for this cancer is desperately needed. Complicating the search for such a modality is that most large molecules cannot pass through the blood brain barrier
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico